Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Theriva Biologics (TOVX) has provided an announcement.
Theriva Biologics, Inc. has received Rare Pediatric Drug Designation from the FDA for its leading drug candidate, VCN-01, targeting the treatment of retinoblastoma, a type of eye cancer in children. This follows a previous orphan drug designation for the same treatment, underscoring the importance and potential of VCN-01. Additionally, the company announced a conversion of its Series C Convertible Preferred Stock into common shares, reflecting ongoing financial developments within the company.
Learn more about TOVX stock on TipRanks’ Stock Analysis page.